fbpx

FDA Sued Over Inaction on Dangerous Hair Loss Medication Propecia

In early September, Public Citizen, on behalf of Post-Finasteride Syndrome Foundation (PFSF), filed a lawsuit against the U.S. Food and Drug Administration (FDA) regarding their inaction on a petition submitted four years ago. PFSF asked, in 2017, that the FDA remove Propecia, a popular medication for male pattern baldness, from market. The drug has been linked to increased risk of depression suicidal ideation, and long-term erected dysfunction. 

Lawsuit History Between PFSF and the FDA

Prescriptions for Propecia, the brand-name version of 1mg finasteride, have increased in recent years, as the medication as well as its generic versions are often seen in television and online advertisements. As an alternative to the initial request for the FDA to withdraw its approval of the drug, PFSF asked that drug manufacturers revise the safety information on the labels to warn consumers of potential side effects. The lawsuit filed last month argues that the FDA has acted unlawfully by failing to respond on the original petition. 

“The FDA needs to act in a timely way to protect the public from the risks associated with use of Propecia,” said Michael Kirkpatrick, who is serving as lead counsel for PFSF. “The FDA’s failure to act exposes consumers to potentially life-threatening harm.”

Risks of Long-Term Use of Propecia

Long-term use of the hair loss medication can lead to post-finasteride syndrome (PFS), which causes sexual dysfunction and psycho-neurocognitive symptoms, including issues related to mood, sleep, stress response, and more. Unfortunately, men with a PFS diagnosis may suffer from these side effects for years after they stop taking the drug.

The increased risk of suicide after taking finasteride has been studied for years. Vigibase, a global database that tracks harmful side effects from pharmacovigilance agencies, reveals 378 cases of suicidal ideation, 39 suicide attempts, and 88 suicides as a result of finasteride use. Moreover, a study from 2020 found that patients under 45 were particularly vulnerable to depression, anxiety, and suicidal thoughts. 

“False information from the FDA leads physicians to dismiss patients, while some even tell them their symptoms are not real,” shared John Santmann, M.D., the head of PFSF. “Without effective treatments for PFS, use of this cosmetic drug can lead to a lifetime of side effects. The drug ruins more lives every day and has no business being on the market.”

For more information about the lawsuit concerning Propecia, contact us today.

Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.